Login to Your Account

ASCO 2010

Data Back Celgene's Revlimid in Multiple Myeloma Maintenance

By Trista Morrison

Tuesday, June 8, 2010
As the American Society of Clinical Oncology (ASCO) annual meeting continued over the weekend, Celgene Corp. made a splash with data from two Phase III studies that analysts believe will convince doctors to use Revlimid (lenalidomide) as maintenance therapy in multiple myeloma (MM). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription